New CAR T-cell data show 100% MRD negativity in high-risk smoldering multiple myeloma, a novel CAR T approach for AML, and a new T-cell pathway, while a case report warns of a rare therapy-related complication.
A phase 2 trial in high-risk smoldering multiple myeloma found all 20 patients treated with cilta-cel became MRD-negative within two months and remained so after 15.3 months. No disease progression, death, dose-limiting toxicities, or high-grade side effects were observed.
The multiple myeloma treatment landscape is rapidly expanding with over 75 companies developing 80+ pipeline therapies, while clinicians navigate evolving questions about transplant timing, quadruplet regimens, and minimal residual disease testing in newly diagnosed patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05469893 |
Immuno-PRISM (PRecision Intervention Smoldering Myeloma) |
RECRUITING | PHASE2 |
| NCT04775550 |
DARA RVD For High Risk SMM |
ACTIVE_NOT_RECRUITING | PHASE2 |
